Abstract
CD20 was the first B cell surface Ag identified as a regulator of B cell function in 1985 ([1][1]) and the anti-CD20 Ab rituximab was the first therapeutic Ab approved for the treatment of B cell neoplasia. Yet the precise functions of CD20 and its Abs are still controversial issues ([2][2]). The
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Published version (
Free)
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
